skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 59,510  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Refined by: subject: Disease Transmission remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Material Type:
Article 		Add to My Research

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact

Nature reviews. Immunology, 2022-01, Vol.22 (1), p.57-65 [Peer Reviewed Journal]

2021. Springer Nature Limited. ;COPYRIGHT 2022 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1474-1733 ;EISSN: 1474-1741 ;DOI: 10.1038/s41577-021-00662-4 ;PMID: 34876702

Full text available

Citations Cited by
2
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Material Type:
Article 		Add to My Research

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

New England Journal of Medicine, 2021-06, Vol.384 (23), p.2187-2201 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2101544 ;PMID: 33882225

Digital Resources/Online E-Resources

Citations Cited by
3
Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study
Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study
Material Type:
Article 		Add to My Research

Dynamic Public Health Surveillance to Track and Mitigate the US COVID-19 Epidemic: Longitudinal Trend Analysis Study

Journal of medical Internet research, 2020-12, Vol.22 (12), p.e24286-e24286 [Peer Reviewed Journal]

Lori Ann Post, Tariq Ziad Issa, Michael J Boctor, Charles B Moss, Robert L Murphy, Michael G Ison, Chad J Achenbach, Danielle Resnick, Lauren Nadya Singh, Janine White, Joshua Marco Mitchell Faber, Kasen Culler, Cynthia A Brandt, James Francis Oehmke. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 03.12.2020. ;Copyright Gunther Eysenbach MD MPH, Associate Professor Dec 2020 ;Lori Ann Post, Tariq Ziad Issa, Michael J Boctor, Charles B Moss, Robert L Murphy, Michael G Ison, Chad J Achenbach, Danielle Resnick, Lauren Nadya Singh, Janine White, Joshua Marco Mitchell Faber, Kasen Culler, Cynthia A Brandt, James Francis Oehmke. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 03.12.2020. 2020 ;ISSN: 1438-8871 ;ISSN: 1439-4456 ;EISSN: 1438-8871 ;DOI: 10.2196/24286 ;PMID: 33216726

Full text available

Citations Cited by
4
Considerations in boosting COVID-19 vaccine immune responses
Considerations in boosting COVID-19 vaccine immune responses
Material Type:
Article 		Add to My Research

Considerations in boosting COVID-19 vaccine immune responses

The Lancet (British edition), 2021-10, Vol.398 (10308), p.1377-1380 [Peer Reviewed Journal]

2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;2021. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;2021 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)02046-8 ;PMID: 34534516

Full text available

Citations Cited by
5
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Material Type:
Article 		Add to My Research

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

New England Journal of Medicine, 2022-03, Vol.386 (13), p.1207-1220 [Peer Reviewed Journal]

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;2022. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2022 Massachusetts Medical Society. All rights reserved. 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2118691 ;PMID: 35172051

Digital Resources/Online E-Resources

Citations Cited by
6
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Material Type:
Article 		Add to My Research

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

Science, 2021-02, Vol.371 (6532) [Peer Reviewed Journal]

2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1126/science.abe6959

Digital Resources/Online E-Resources

Citations Cited by
7
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Material Type:
Article 		Add to My Research

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

The lancet oncology, 2021-06, Vol.22 (6), p.765-778 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00213-8 ;PMID: 33930323

Full text available

Citations Cited by
8
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Material Type:
Article 		Add to My Research

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Nature (London), 2021-05, Vol.593 (7857), p.136-141 [Peer Reviewed Journal]

Copyright Nature Publishing Group May 6, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03412-7 ;PMID: 33706364

Full text available

Citations Cited by
9
How bad is Omicron? What scientists know so far
How bad is Omicron? What scientists know so far
Material Type:
Article 		Add to My Research

How bad is Omicron? What scientists know so far

Nature (London), 2021-12, Vol.600 (7888), p.197-199 [Peer Reviewed Journal]

Copyright Nature Publishing Group Dec 9, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-021-03614-z ;PMID: 34857948

Full text available

Citations Cited by
10
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
Material Type:
Article 		Add to My Research

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

The Lancet infectious diseases, 2021-11, Vol.21 (11), p.1529-1538 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2021 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(21)00289-9 ;PMID: 34174193

Full text available

Citations Cited by
11
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy
Material Type:
Article 		Add to My Research

Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy

Nature medicine, 2021-06, Vol.27 (6), p.993-998 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-021-01334-5 ;PMID: 33864052

Full text available

Citations Cited by
12
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Material Type:
Article 		Add to My Research

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

New England Journal of Medicine, 2021-09, Vol.385 (13), p.1172-1183 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2107659 ;PMID: 34192426

Digital Resources/Online E-Resources

Citations Cited by
13
Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis
Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis
Material Type:
Article 		Add to My Research

Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis

BMJ (Online), 2021-11, Vol.375, p.e068302-e068302 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. BMJ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 BMJ ;ISSN: 1756-1833 ;ISSN: 0959-8138 ;EISSN: 1756-1833 ;DOI: 10.1136/bmj-2021-068302 ;PMID: 34789505

Full text available

Citations Cited by
14
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Material Type:
Article 		Add to My Research

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Nature (London), 2021-05, Vol.593 (7857), p.142-146 [Peer Reviewed Journal]

Copyright Nature Publishing Group May 6, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03471-w ;PMID: 33780970

Full text available

Citations Cited by
15
Dynamic Panel Data Modeling and Surveillance of COVID-19 in Metropolitan Areas in the United States: Longitudinal Trend Analysis
Dynamic Panel Data Modeling and Surveillance of COVID-19 in Metropolitan Areas in the United States: Longitudinal Trend Analysis
Material Type:
Article 		Add to My Research

Dynamic Panel Data Modeling and Surveillance of COVID-19 in Metropolitan Areas in the United States: Longitudinal Trend Analysis

Journal of medical Internet research, 2021-02, Vol.23 (2), p.e26081 [Peer Reviewed Journal]

Theresa B Oehmke, Lori A Post, Charles B Moss, Tariq Z Issa, Michael J Boctor, Sarah B Welch, James F Oehmke. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 09.02.2021. ;2021. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Theresa B Oehmke, Lori A Post, Charles B Moss, Tariq Z Issa, Michael J Boctor, Sarah B Welch, James F Oehmke. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 09.02.2021. 2021 ;ISSN: 1438-8871 ;ISSN: 1439-4456 ;EISSN: 1438-8871 ;DOI: 10.2196/26081 ;PMID: 33481757

Full text available

Citations Cited by
16
How severe are Omicron infections?
How severe are Omicron infections?
Material Type:
Article 		Add to My Research

How severe are Omicron infections?

Nature (London), 2021-12, Vol.600 (7890), p.577-578 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;Copyright Nature Publishing Group Dec 23-Dec 30, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/d41586-021-03794-8 ;PMID: 34934198

Full text available

Citations Cited by
17
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
Material Type:
Article 		Add to My Research

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Nature (London), 2021-08, Vol.596 (7871), p.273-275 [Peer Reviewed Journal]

2021. The Author(s), under exclusive licence to Springer Nature Limited. ;COPYRIGHT 2021 Nature Publishing Group ;Copyright Nature Publishing Group Aug 12, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03693-y ;PMID: 34111888

Full text available

Citations Cited by
18
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
Material Type:
Article 		Add to My Research

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose

The Lancet (British edition), 2022-02, Vol.399 (10325), p.625-626 [Peer Reviewed Journal]

2022 Elsevier Ltd ;2022. Elsevier Ltd ;2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00090-3 ;PMID: 35063123

Full text available

Citations Cited by
19
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
Material Type:
Article 		Add to My Research

New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications

New England Journal of Medicine, 2021-05, Vol.384 (19), p.1866-1868 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc2100362 ;PMID: 33761203

Digital Resources/Online E-Resources

Citations Cited by
20
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Material Type:
Article 		Add to My Research

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

The Lancet (British edition), 2021-04, Vol.397 (10282), p.1351-1362 [Peer Reviewed Journal]

2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;COPYRIGHT 2021 Elsevier B.V. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00628-0 ;PMID: 33798499

Full text available

Citations Cited by

Results 1 - 20 of 59,510  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (37,442)

Refine My Results

Creation Date 

From To
Refine
  1. Before 2013  (2)
  2. 2013 To 2014  (3)
  3. 2015 To 2018  (3)
  4. 2019 To 2021  (36,966)
  5. After 2021  (22,539)
  6. More options open sub menu

Subject 

  1. Covid-19  (54,836)
  2. Coronaviruses  (53,533)
  3. Pandemics  (38,806)
  4. Science & Technology  (31,262)
  5. Life Sciences & Biomedicine  (25,892)
  6. Severe Acute Respiratory Syndrome Coronavirus 2  (22,211)
  7. Infections  (16,421)
  8. Public Health  (15,308)
  9. Humans  (14,993)
  10. Epidemics  (14,227)
  11. Sars-Cov-2  (11,956)
  12. Covid-19 Vaccines  (11,007)
  13. Viruses  (8,696)
  14. Viral Diseases  (8,639)
  15. Infectious Diseases  (8,049)
  16. Patients  (7,558)
  17. Vaccines  (6,989)
  18. Medical Research  (6,881)
  19. Health Aspects  (5,959)
  20. More options open sub menu

Language 

  1. English  (59,326)
  2. Japanese  (2,269)
  3. Portuguese  (253)
  4. French  (170)
  5. Spanish  (135)
  6. Turkish  (101)
  7. Chinese  (70)
  8. German  (65)
  9. Norwegian  (25)
  10. Afrikaans  (21)
  11. Italian  (16)
  12. Polish  (13)
  13. Dutch  (5)
  14. Malay  (5)
  15. Hungarian  (4)
  16. Russian  (4)
  17. Romanian  (4)
  18. Indonesian  (3)
  19. Croatian  (3)
  20. Slovenian  (3)
  21. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait